GlassScriptPhysician profile
Winston C Chua
NPI 1013923846
$5,012.72
in general payments reported to CMS, 2019-2025
55 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,104 · 2020: $441 · 2021: $656 · 2022: $281 · 2023: $722 · 2024: $515 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.57 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $456.22 | 2019-2025 | |
| Janssen Biotech, INC. | $390.03 | 2019-2023 | Darzalex, Imbruvica, Tecvayli |
| Merck Sharp & Dohme LLC | $360.57 | 2019-2025 | Lynparza, Keytruda, Welireg |
| Astellas Pharma US INC | $295.04 | 2019-2024 | Xtandi, Padcev |
| Novartis Pharmaceuticals Corporation | $292.49 | 2019-2025 | |
| Seagen INC. | $241.34 | 2019-2023 | Tukysa, Adcetris |
| Amgen INC. | $205.97 | 2019-2022 | |
| Lilly USA, LLC | $160.69 | 2019-2023 | Jaypirca, Retevmo, Verzenio |
| Celgene Corporation | $147.14 | 2020-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $133.43 | 2019-2024 | Opdualag, Augtyro |
| Gilead Sciences, INC. | $124.10 | 2019-2024 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $117.64 | 2019-2023 | Imbruvica |
| Daiichi Sankyo INC. | $110.92 | 2019-2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $105.31 | 2019-2024 | Imfinzi, Enhertu |
| Teva Pharmaceuticals USA, INC. | $103.41 | 2019-2020 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Winston Chua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.